179 related articles for article (PubMed ID: 21171673)
1. Tofacitinib.
Adis Editorial
Drugs R D; 2010; 10(4):271-84. PubMed ID: 21171673
[TBL] [Abstract][Full Text] [Related]
2. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
West K
Curr Opin Investig Drugs; 2009 May; 10(5):491-504. PubMed ID: 19431082
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib in kidney transplantation.
Wojciechowski D; Vincenti F
Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
5. Targeting JAK3 in kidney transplantation: current status and future options.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2011 Dec; 16(6):614-9. PubMed ID: 21971513
[TBL] [Abstract][Full Text] [Related]
6. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Di Lernia V; Bardazzi F
Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
[TBL] [Abstract][Full Text] [Related]
7. Treating inflammation with the Janus kinase inhibitor CP-690,550.
Vijayakrishnan L; Venkataramanan R; Gulati P
Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib for the treatment of moderate to severe rheumatoid arthritis.
de Lartigue J
Drugs Today (Barc); 2012 Aug; 48(8):533-43. PubMed ID: 22916341
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib for the treatment of rheumatoid arthritis.
Zerbini CA; Lomonte AB
Expert Rev Clin Immunol; 2012 May; 8(4):319-31. PubMed ID: 22607178
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
Rovira J; Ramírez-Bajo MJ; Banon-Maneus E; Lazo-Rodríguez M; Moya-Rull D; Hierro-Garcia N; Tubita V; Piñeiro GJ; Revuelta I; Ventura-Aguiar P; Cucchiari D; Oppenheimer F; Brunet M; Campistol JM; Diekmann F
Transplantation; 2018 Jul; 102(7):1075-1084. PubMed ID: 29620612
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib for treatment of rheumatoid arthritis.
Rakieh C; Conaghan PG
Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib (Xeljanz) for rheumatoid arthritis.
Med Lett Drugs Ther; 2013 Jan; 55(1407):1-3. PubMed ID: 23288133
[No Abstract] [Full Text] [Related]
15. The specificity of JAK3 kinase inhibitors.
Changelian PS; Moshinsky D; Kuhn CF; Flanagan ME; Munchhof MJ; Harris TM; Whipple DA; Doty JL; Sun J; Kent CR; Magnuson KS; Perregaux DG; Sawyer PS; Kudlacz EM
Blood; 2008 Feb; 111(4):2155-7. PubMed ID: 18094329
[TBL] [Abstract][Full Text] [Related]
16. Jak3 deficiency blocks innate lymphoid cell development.
Robinette ML; Cella M; Telliez JB; Ulland TK; Barrow AD; Capuder K; Gilfillan S; Lin LL; Notarangelo LD; Colonna M
Mucosal Immunol; 2018 Jan; 11(1):50-60. PubMed ID: 28513593
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib in psoriatic arthritis.
Wang TS; Tsai TF
Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
[TBL] [Abstract][Full Text] [Related]
18. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
Changelian PS; Flanagan ME; Ball DJ; Kent CR; Magnuson KS; Martin WH; Rizzuti BJ; Sawyer PS; Perry BD; Brissette WH; McCurdy SP; Kudlacz EM; Conklyn MJ; Elliott EA; Koslov ER; Fisher MB; Strelevitz TJ; Yoon K; Whipple DA; Sun J; Munchhof MJ; Doty JL; Casavant JM; Blumenkopf TA; Hines M; Brown MF; Lillie BM; Subramanyam C; Shang-Poa C; Milici AJ; Beckius GE; Moyer JD; Su C; Woodworth TG; Gaweco AS; Beals CR; Littman BH; Fisher DA; Smith JF; Zagouras P; Magna HA; Saltarelli MJ; Johnson KS; Nelms LF; Des Etages SG; Hayes LS; Kawabata TT; Finco-Kent D; Baker DL; Larson M; Si MS; Paniagua R; Higgins J; Holm B; Reitz B; Zhou YJ; Morris RE; O'Shea JJ; Borie DC
Science; 2003 Oct; 302(5646):875-8. PubMed ID: 14593182
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
Borie DC; Changelian PS; Larson MJ; Si MS; Paniagua R; Higgins JP; Holm B; Campbell A; Lau M; Zhang S; Flores MG; Rousvoal G; Hawkins J; Ball DA; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Morris RE
Transplantation; 2005 Apr; 79(7):791-801. PubMed ID: 15818321
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.
Martina MN; Ramirez Bajo MJ; Bañon-Maneus E; Moya Rull D; Hierro-Garcia N; Revuelta I; Campistol JM; Rovira J; Diekmann F
Transplant Proc; 2016 Nov; 48(9):3046-3052. PubMed ID: 27932144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
